Tetraphase Pharmaceuticals Inc. (TTPH) Receives $10.41 Average Price Target from Brokerages
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) has earned an average recommendation of “Hold” from the seven research firms that are presently covering the firm. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $10.41.
A number of equities analysts have recently commented on TTPH shares. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a report on Tuesday, October 11th. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Tetraphase Pharmaceuticals in a report on Friday, August 5th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $6.00 price target on shares of Tetraphase Pharmaceuticals in a report on Friday, November 4th.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 4.02 on Wednesday. The firm has a 50-day moving average of $3.68 and a 200 day moving average of $4.03. Tetraphase Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $12.45. The company’s market capitalization is $148.35 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.08. The company earned $0.90 million during the quarter, compared to the consensus estimate of $1.58 million. Tetraphase Pharmaceuticals had a negative return on equity of 39.95% and a negative net margin of 1,120.67%. Tetraphase Pharmaceuticals’s quarterly revenue was down 69.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) EPS. On average, equities research analysts expect that Tetraphase Pharmaceuticals will post ($2.10) earnings per share for the current year.
Several large investors have recently made changes to their positions in TTPH. Bellevue Group AG acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth about $102,000. Nisa Investment Advisors LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 2,618.8% in the second quarter. Nisa Investment Advisors LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 41,900 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter valued at $257,000. Candriam Luxembourg S.C.A. boosted its stake in shares of Tetraphase Pharmaceuticals by 31.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 374,000 shares of the biopharmaceutical company’s stock valued at $1,608,000 after buying an additional 90,000 shares during the last quarter. Finally, Emerald Acquisition Ltd. purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter valued at $318,000. 59.30% of the stock is owned by institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.